Nesiritide: New hope for acute heart failure syndromes?

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


B-type natriuretic peptide (BNP) is a peptide hormone that exerts cardiac, renal, and hormonal effects, and is produced by the myocardium as part of the compensatory response of the failing heart. The therapeutic benefits of exogenous BNP administration to patients with acute heart failure syndromes have been demonstrated, and recombinant human BNP (nesiritide) was licensed in the USA for the treatment of this condition in 2001. Recent studies have also found that the beneficial effects of BNP in patients with heart failure extend beyond haemodynamics, to include natriuretic, renoprotective, and anti-remodelling properties. New therapeutic opportunities for BNP are also under investigation, including the possibility of long-term use in patients with chronic congestive heart failure.

Original languageEnglish (US)
Pages (from-to)B25-B30
JournalEuropean Heart Journal, Supplement
Issue numberB
StatePublished - Apr 2005


  • Acute disease
  • B-type natriuretic peptide
  • Congestive heart failure
  • Pathophysiology/prevention and control/therapy
  • Pharmacotherapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Nesiritide: New hope for acute heart failure syndromes?'. Together they form a unique fingerprint.

Cite this